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Background: The role of chemotherapy in the treatment of metastatic male breast cancer patients remains unknown,
and the only available evidence stem from small, retrospective series evaluating outdated drugs and/or regimens.
Methods: In this retrospective study we evaluated the activity of polychemotherapy, consisting of three-drug
(anthracycline-containing and anthracycline-free) regimens, as a first-line therapy for metastatic male breast cancer
patients who had received at least one prior endocrine therapy.
Results: Fifty patients treated between 1978 and 2013 were included in the present analysis. Regarding best response,
we recorded 1 (2%) complete response and 27 (54%) partial responses, for an overall response rate of 56% (95% CI,
42.2-69.8). Considering stable disease, the disease control rate was 84%. Median progression-free survival was
7.2 months (95% CI, 5.9-8.5), and median overall survival was 14.2 months (95% CI, 12.2-16.2). Albeit we observed some
differences for all the outcomes explored when comparing anthracycline-containing and anthracycline-free regimens,
they were not statistically significant.
Conclusions: Chemotherapy, consisting in both anthracycline-containing and anthracycline-free regimens, showed
encouraging antitumor activity in metastatic male breast cancer patients previously treated with endocrine therapy.
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Male breast cancer (MBC) is a rare disease accounting
for less than 1% of all breast cancer (BC) cases [1]. Pa-
tients who develop a metastatic disease are mainly
treated with anti-hormone therapies [2]. Initial hints on
the therapeutic potential of manipulating the hormonal
background dates back to the 1940s when endocrine
surgery (orchiectomy, adrenalectomy and hypophysec-
tomy) was associated with tumor regressions [3]. The
use of hormonal treatments has found more concrete
ground with investigations aimed at providing molecular
information to assist in clinical decision-making [4]. Col-
lectively, estrogen and progesterone receptors were de-
tected as often expressed in MBC, even more frequently* Correspondence: maugeri@ifo.it
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unless otherwise stated.than in female BC (FBC) [4]. A therapeutic role for the
androgen receptor was more recently envisioned based
on immunohistochemical and gene expression profile
studies [5,6].
Thus, the current treatment paradigm for metastatic
MBC patients (mMBC) relies on the concept of delaying
chemotherapy as long as possible with the use of se-
quential anti-hormonal treatments. A number of factors
account for this approach. Firstly, the wealth of hormo-
nal medical treatments available, including tamoxifen
[7], aromatase inhibitors [8-11], fulvestrant [12,13] and
anti-androgens [14-16]. Though retrospectively, all the
afore-mentioned compounds showed clinical activity
[7-16]. Secondly, the lesson we learned from FBC is that
chemotherapy is overall less effective in endocrine-
responsive tumours. Thirdly, MBC is a disease of elderly
men [1], for whom the harm possibly deriving from che-
motherapeutic agents along with the often co-existing
comorbidities refrain from using chemotherapy. Finally,l. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Baseline characteristics in metastatic male breast
cancer patients treated with first-line chemotherapy
following endocrine therapy (N = 50)
Characteristic N %
Age
Median 66 -
Range 24-78 -
ECOG PS
Median 1 -
Range 0-2 -
Hormone receptor status
Positive 48 96
Unknown 2 4
HER2 status
Negative 19 38
Unknown 31 62
Adjuvant CT
Yes 5 10
No 45 90
Lines of HT for advanced disease
Median 1 -
Range 1-3 -
Dominant disease site
Visceral 38 76
Bone 10 20
Soft-tissue 2 4
Number of disease sites
1 10 20
2 25 50
≥3 15 30
Chemotherapy regimens
FAC 21 42
FEC 11 22
TEC 3 6
CMF (intravenous) 10 20
CMF (oral) 5 10
ECOG PS: Eastern Cooperative Oncology Group Performance Status;
CT: chemotherapy; HT: hormonal therapy; FAC: Fluorouracil, Doxorubicin and
Cyclophosphamide; FEC: Fluorouracil, Epirubicin and Cyclophosphamide;
TEC: Docetaxel, Epirubicin and Cyclophosphamide; CMF: Cyclophosphamide,
Methotrexate and Fluorouracil.
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population are scarce and stem from retrospective, small-
sized studies either reporting on outdated drugs/regi-
mens [17,18] or with no clear focus on chemotherapy
efficacy [19].
Nevertheless, the natural history of the disease, during
which adaptive changes arisen following prolonged drug
administration render cancer cells no longer dependent
on hormonal stimuli, forces clinicians to consider chemo-
therapy. In this context, however, uncertainty dominates,
and daily clinical management of patients no longer bene-
fiting from anti-hormone treatments is largely empirical.
Owing to the gap existing in current medical literature,
we herein describe our clinical experience with polyche-
motherapy in the treatment of mMBC patients.
Methods
The study population was composed by 50 metastatic
MBC patients who received polychemotherapy. All pa-
tients had received at least one prior hormonal treatment
in the metastatic setting. All patients were treated between
1978–2013. The majority of patients was clinically man-
aged at the “Regina Elena” National Cancer Institute,
Rome. Medical records were reviewed in order to obtain
information on demography, molecular pathology, treat-
ment administered and outcomes. Patients received the
following regimens: 5-fluorouracil, doxorubicin and cyclo-
phosphamide (FAC) 500/50/500 mg/m2 every 3 weeks, 5-
fluorouracil, epirubicin and cyclophosphamide (FEC) 500/
75/500 mg/m2 every 3 weeks, docetaxel, epirubicin and
cyclophosphamide (TEC) 75/75/500 mg/m2 every 3 weeks,
intravenous cyclophosphamide, methotrexate and 5-
fluorouracil (CMF/iv) 600/40/600 mg/m2 on days l and 8
every 4 weeks, or oral cyclophosphamide, methotrexate
and 5-fluorouracil (CMF/oral) 100/40/600 with cyclo-
phosphamide given orally d1-14. Treatment was contin-
ued until disease progression, unacceptable toxicity, death,
and for a maximum of 6 cycles. As our patients were
treated over a period of ~35 years, tumor response was
evaluated according to the criteria outlined by the Inter-
national Union Against Cancer, the World Health
Organization [20,21] or the Response Evaluation Criteria
In Solid Tumors (RECIST 1.1). Progression-free survival
(PFS) and overall survival (OS) were calculated from the
date of therapy initiation to the date of disease progression
or death from any cause, respectively. PFS and OS were
analyzed according to the Kaplan-Meier method. Compar-
isons between regimens were performed using the log-
rank test. All statistical analyses were performed using
SPSS statistical software version 20 (SPSS inc., Chicago IL,
USA). This retrospective study was approved by the Ethic
Committee of “Regina Elena” National Cancer Institute of
Rome, the coordinating centre, and was carried out ac-
cording to the Helsinki Declaration.Results
Fifty patients (median age: 66 years, range: 24–78) treated
between 1978 and 2013 were included in this study. Pa-
tients’ characteristics are illustrated in Table 1. All patients
had received at least one prior hormonal treatment for
their metastatic disease. In the first-line setting 24 patients
received cyproterone acetate (either as a monotherapy or
combined with a GnRH analogue), 15 patients received
Table 2 Objective response to first-line chemotherapy in
metastatic male breast cancer (N = 50)
Responses Overall Antra-based
chemotherapy
Non antra-based
chemotherapy
N % N % N %
Complete response 1 2 1 2.9 - -
Partial response 27 54 20 57.1 7 46.7
Stable disease 14 28 9 25.7 5 33.3
Progressive disease 8 16 5 14.3 3 20
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zole, 6 tamoxifen and 1 exemestane. The median number
of prior therapy with anti-hormonal agents for advanced
disease was 1 (range 1–3). Forty-eight tumors (96%) were
estrogen and/or progesterone receptor-positive. HER2 sta-
tus was negative or unknown in all tumors. Thirty-eight
patients (76%) had visceral metastases. None of them had
brain metastases at the beginning of chemotherapy. Forty
patients (80%) had 2 or more metastatic sites.
Overall response rate (ORR) was 56% (95% CI, 42.2-
69.8). In detail, we recorded 1 (2%) complete response
(CR) in a patient with liver and skin metastases treated
with TEC, and 27 (54%) partial responses (PR). Stable
disease (SD) was observed in 14 patients (28%). Disease
control rate (DCR), defined as CR + PR + SD, was 84%.
Progressive disease (PD) was seen in 8 patients (16%).
ORR was 60% in patients treated with anthracycline-
containing regimens and 46.7% in patients treated with
anthracycline-free regimens (Table 2).
Median PFS (mPFS) was 7.2 months in the entire popu-
lation (95% CI, 5.9-8.5) (Figure 1), 7.5 months in patients
treated with anthracycline-containing regimens (95% CI,
5.5-9.5), and 6.5 months in patients treated with CMF
(95% CI, 5.0-8.0). Five patients (10%) were free from dis-
ease progression after 1 year.
Median OS (mOS) was 14.2 months in the entire
population (95% CI, 12.2-16.2) (Figure 1), 14.9 months in
patients treated with anthracycline-containing regimensFigure 1 Kaplan-Meier survival curves regarding A) PFS and B) OS.(95% CI, 12.8-17.0), and 13.0 months in patients treated
with CMF (95% CI, 9.6-16.4). One-year survival rate was
68% in the entire population, 71.4% in patients treated
with anthracycline-containing regimens, and 53.3% in pa-
tients treated with anthracycline-free regimens.
Irrespective of the clinical outcome analyzed, the
observed differences between anthracycline-containing
and anthracycline-free regimens were not statistically
significant.
Discussion
In this study, we reported on the efficacy of chemother-
apy, consisting of three-drug anthracycline-containing
and anthracycline-free regimens, in a series of 50 mMBC
pretreated with endocrine treatments. To our know-
ledge, this is the largest series describing the efficacy of
chemotherapy in this population.
In order to put our results into context, some intrinsic
pitfalls firstly need to be discussed. The retrospective na-
ture of our study ranks first. Unfortunately, lack of pro-
spective data from randomized trials chronically plague
the clinical management of these patients. To stress the
concept that carrying out prospective studies in mMBC
is extremely challenging, as already outlined elsewhere
[2,22], poor accrual forced to prematurely close a small-
sized study initiated by the SWOG cooperative group
(SWOG-S0511, ClinicalTrials.gov; ID: NCT00217659).
Recently, both the German Breast Group (ClinicalTrials.
gov; ID: NCT01638247) and the European Organization
for Research and Treatment of Cancer (ClinicalTrials.
gov; ID: NCT01101425) promoted research in MBC.
However, while attention is focused on hormonal ther-
apy in the first case, the latter, to our knowledge, does
not envision prospective, interventional trials but rather
predominantly focuses on clinical and molecular char-
acterization. We and others have recently discussed some
strategies for overcoming this hurdle, such as including a
pre-specified number of mMBC patients into prospective
FBC trials [2,22]. In our opinion, however, this approach
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“exceptional” responders in a background of oncogene ad-
diction, rather than with chemotherapy-focusing investi-
gations. More realistically, we would like to encourage
clinicians to collect information on the use of chemother-
apy in the metastatic setting in order to strength our data
and promote pooled analyses.
The heterogeneity in the modalities used for assessing
disease extension and evolution, encompassing both im-
aging techniques and response criteria [20,21], deserves
to be mentioned. We are aware that the efficacy of
chemotherapy was not exactly captured in our study.
Nonetheless, with an ORR of 56% encouraging signs of
antitumor activity were registered.
Finally, the impossibility to retrieve safety data should
be considered, with the solely exception of a fraction of
patients treated in the most recent years, owing to the
wide time window considered. Based on currently avail-
able, albeit incomplete, data we did not observe any un-
expected warnings in terms of toxicity and adherence to
therapy.
Looking at the data herein presented from a different
angle the message conveyed is that established chemo-
therapy regimens commonly used in the female setting
are also effective in mMBC patients after endocrine
therapies. Thus, for patients with good performance sta-
tus a series of conditions legitimize, in our opinion, the
delivery of palliative chemotherapy including progres-
sion after multiple endocrine treatments, unacceptable
hormone therapy-related side effects, rapidly progressive
lesions, or lack of hormone receptor expression.Conclusions
Chemotherapy with anthracycline-containing and anthra-
cycline-free regimens appears an effective treatment op-
tion for mMBC patients previously treated with endocrine
therapy.
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